Association between longer therapy with thiazolidinediones and risk of bladder cancer: A cohort study

Journal of the National Cancer Institute

Volumn 104, Issue 18, 2012, Pages 1411-1421

  Mamtani, Ronac ^a   Haynes, Kevin ^b   Bilker, Warren B ^b   Vaughn, David J ^a   Strom, Brian L ^b   Glanz, Karen ^b   Lewis, James D ^a  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ADULT; ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84866707482     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs328     Document Type: Article

References (49)

1. FDA Drug Safety Communication. Update to Ongoing Safety Review of Actos (Pioglitazone) and Increased Risk of Bladder Cancer. http://www.fda.gov/Drugs/ DrugSafety/ucm259150.htm. Accessed July 21, 2011.
2. Demetri GD, Fletcher CD, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA. 1999;96(7):3951-3956.
3. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA. 2000;97(20):10990-10995.
4. Nakashiro KI, Hayashi Y, Kita A, et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol. 2001;159(2):591-597.
5. Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003;104(5):597-602.
6. Chang AJ, Song DH, Wolfe MM. Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation. J Biol Chem. 2006;281(21):14700-14710.
7. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther. 2006;5(2):430-437.
8. Nunez NP, Liu H, Meadows GG. PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett. 2006;236(1):133-141.
9. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916-922.
10. Caisse National d'Assurance Maladie. Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France: une étude de cohorte sur les données du SNIIRAM et du PMSI. Afssaps (French Agency for the Safety of Health Products). 2011.
11. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
12. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14.
13. Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA warning-geographic variation in the use of rosiglitazone. N Engl J Med. 2010;363(22):2081-2084.
14. Chisholm J. The Read clinical classification. BMJ. 1990;300(6732):1092.
15. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16(4):393-401.
16. Meal A, Leonardi-Bee J, Smith C, Hubbard R, Bath-Hextall F. Validation of THIN data for non-melanoma skin cancer. Qual Prim Care. 2008;16(1):49-52.
17. Hall GC. Validation of death and suicide recording on the THIN UK primary care database. Pharmacoepidemiol Drug Saf. 2009;18(2):120-131.
18. Lo Re V, III, Haynes K, Forde KA, Localio AR, Schinnar R, Lewis JD. Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf. 2009;18(9):807-814.
19. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010;60(572):e128-136.
20. Denburg MR, Haynes K, Shults J, Lewis JD, Leonard MB. Validation of The Health Improvement Network (THIN) database for epidemiologic studies of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2011;20(11):1138-1149.
21. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12(3):171-177.
22. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
23. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129(1):125-137.
24. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84(408):1074-1078.
25. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.
26. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998;54(3):948-963.
27. Sorensen HT, Friis S, Norgard B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003;88(11):1687-1692.
28. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602-1612.
29. Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ. 2012;344(7854):e2697.
30. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer. 2011;11:409.
31. Takeda Pharmaceuticals America Inc. Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information. http://www.actos.com/WhatIsIt.aspx. Accessed August 26, 2010.
32. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49(12):2819-2823.
33. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia. 2011;54(8):2009-2015.
34. Li C, Balluz LS, Ford ES, Okoro CA, Tsai J, Zhao G. Association between diagnosed diabetes and self-reported cancer among U.S. adults: findings from the 2009 Behavioral Risk Factor Surveillance System. Diabetes Care. 2011;34(6):1365-1368.
35. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer. 2011;117(7):1552-1556.
36. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35(2):278-280.
37. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4-14.
38. Haynes K, Forde KA, Schinnar R, Wong P, Strom BL, Lewis JD. Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2009;18(8):730-736.
39. Office for National Statistics. Average Number of New Cases Per Year and Age-Specific Incidence Rates per 100,000 Population, UK. http://www.statistics. gov.uk/statbase/Product.asp?vlnk=8843. Accessed September 1, 2010.
40. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
41. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-1188.
42. Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009;169(15):1395-1402.
43. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-1195.
44. Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP. A meta-analysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl. 2008;42(218):64-78.
45. Office for National Statistics. Population Estimates by Ethnic Group 2002-2009: England and Wales. http://www.ons.gov.uk/ons/rel/peeg/population- estimates-by-ethnic-group-experimental-/current-estimates/population-density- change-and-concentration-in-great-britain.pdf. Accessed January 1, 2012.
46. Aquilante CL, Zhang W, McCollum M. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes. Curr Med Res Opin. 2007;23(3):489-494.
47. IMS Health. Top U.S. Pharmaceutical Products by Spending. 2010; http://www. imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20 Room/Top-line%20Market%20Data/2010%20Top-line%20Market%20 Data/2010-Top- Products-by-Sales.pdf. Accessed August 5, 2011.
48. Turner RC, Holman RR, Stratton IM, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
49. Moyer VA. Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;155(4): 246-251.